Evidence map›Paper›PMID 42713489›Full record

ArticleJBMR plus2026

The socioeconomic impacts of fibrodysplasia ossificans progressiva: evidence from a retrospective case-control study in France.

Geneviève Baujat, Stéphane Bouée, Oyinkan Solanke, Kim Croskery, Justin Kirion, Valérie Cormier-Daire, Anne-Sophie Jannot, Viviane Jeanbat, Thomas Funck-Brentano

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Geneviève BaujatService de Médecine Génomique des Maladies Rares, Université Paris Cité, INSERM UMR 1163, Institut Imagine, Hôpital Necker-Enfants malades, Paris 75015,  France.ORCID https://orcid.org/0000-0001-7435-0298
Stéphane BouéeCEMKA, Boulevard Maréchal Joffre, Bourg-La-Reine 92340, France.ORCID https://orcid.org/0000-0001-6838-2680
Oyinkan SolankeMedical Affairs Rare Disease / Global HEOR, Medical Affairs Rare Disease / Global HEOR, Ipsen, London W2 1AF, United Kingdom.ORCID https://orcid.org/0009-0004-2655-9512
Kim CroskeryMedical Affairs Rare Disease / Global HEOR, Medical Affairs Rare Disease / Global HEOR, Ipsen, London W2 1AF, United Kingdom.ORCID https://orcid.org/0000-0002-0607-4022
Justin KirionCEMKA, Boulevard Maréchal Joffre, Bourg-La-Reine 92340, France.ORCID https://orcid.org/0009-0008-0729-7667
Valérie Cormier-DaireService de Médecine Génomique des Maladies Rares, Université Paris Cité, INSERM UMR 1163, Institut Imagine, Hôpital Necker-Enfants malades, Paris 75015,  France.ORCID https://orcid.org/0000-0002-2839-9856
Anne-Sophie JannotBanque Nationale de Données Maladies Rares (Banque Nationale de Données Maladies Rares (BNDMR), Greater Paris University Hospitals (APHP), Paris 75012,  France.ORCID https://orcid.org/0000-0002-8001-8539
Viviane JeanbatCEMKA, Boulevard Maréchal Joffre, Bourg-La-Reine 92340, France.ORCID https://orcid.org/0009-0003-7422-0022
Thomas Funck-BrentanoDepartment of Rheumatology, Lariboisière Hospital, APHP, Nord, Université Paris Cité, Paris 75010,  France.ORCID https://orcid.org/0000-0001-7684-2405

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic bone disorder associated with considerable clinical, economic, and societal impacts on patients, their caregivers, and the healthcare system. The aim of this study was to update the estimated prevalence of FOP in France, characterize the FOP patient population and impact of the disease, assess associated mortality rates, and quantify healthcare resource utilization and socioeconomic costs for individuals with FOP. An observational, retrospective case-control study was conducted using linked data for individuals with FOP from the French National Rare Diseases Registry and the French National Healthcare System Database (SNDS). Results were compared with the SNDS for a control group of individuals with any disease other than FOP. Prevalence of FOP was estimated at 1.39 per million. Data were available for 77 individuals with FOP and 769 controls without FOP. Of 70 individuals with FOP and a social security number at the index date, 50.0% (

Indexed as

comorbiditiesfibrodysplasia ossificans progressivaFrench National Healthcare System DatabaseFrench National Rare Diseases Registryhealthcare resource utilizationmortalityprevalencesocioeconomic costs

Identifiers

PMID42713489
PMCPMC13552502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.